RxDoctor Payments Data

Barton Cohen, MD

Cardiovascular Disease · Great Neck, NYNPI 1194784249

Payments from drug & device makers

$1,449in general payments, 2019–2025

Across 90 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$664
  • Kowa Pharmaceuticals America, Inc.$271
  • Novartis$251
  • United Therapeutics Corporation$100
  • Althera Pharmaceuticals LLC$40
  • Regeneron Healthcare Solutions, Inc.$40
  • plus $83 from 5 others

What the payments were for

  • Speaking & faculty fees$1007%
  • Food & beverage$1,34993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,449 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$200,712
Medicare patients
359
Services billed
3,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$187,576
Repatha SureclickEvolocumab99$98,102
XareltoRivaroxaban43$65,434
Praluent PenAlirocumab55$52,471
OzempicSemaglutide38$50,656
FarxigaDapagliflozin Propanediol31$35,037
MounjaroTirzepatide21$26,579
EntrestoSacubitril/Valsartan21$23,307
JardianceEmpagliflozin12$16,484
LivaloPitavastatin Calcium17$12,223
MultaqDronedarone Hcl14$10,588
Rosuvastatin Calcium552$7,419
JanuviaSitagliptin Phosphate12$6,438
Metoprolol Succinate418$5,927
Atorvastatin Calcium350$3,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$50,65638 claims
NovartisEntresto$251$23,30721 claims
Boehringer IngelheimJardiance$11$16,48412 claims
Kowa Pharmaceuticals America, Inc.Livalo$271$12,22317 claims
Sanofi-aventis U.S. LLCMultaq$21$10,58814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →